Search clinical trials for: Investigational Arm - secukinumab

Total 5419 results

Novartis Pharmaceuticals

Terminated

A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD) (pINPOINt)

Plaque Psoriasis | Non-alcoholic Fatty Liver Disease

Germany, Spain
Limacorporate S.p.a
NAMSA

Recruiting

SMR Stemless Reverse vs SMR Reverse Shoulder System

Arthroplasty, Replacement

United States
Ecole Polytechnique Fédérale de Lausanne

Recruiting

Epidural Electrical Stimulation to Restore Hemodynamic Stability and Trunk Control in People With Spinal Cord Injury (HemON)

Spinal Cord Injuries

Switzerland
Loma Linda University

Completed

Chemotherapy Induced Peripheral Neuropathy (CIPN)

Chemotherapy-induced Peripheral Neuropathy

United States
GlaxoSmithKline

Completed

Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine

Infections, Meningococcal

Germany
Zydus Lifesciences Limited

Recruiting

A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates

Ulcerative Colitis

India
University Hospital, Basel, Switzerland
ETOP IBCSG Partners Foundation; Austrian Breast Cancer Study Group

Recruiting

Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS) (TAXIS)

Node-positive Breast Cancer

Greece, Switzerland, Hungary, Austria, Germany, Italy, Lithuania, Argentina, Croatia
University Hospital, Toulouse

Active, not recruiting

Translation and Transcultural Adaptation of the Arm Activity Measure (ArmA) and Motor Activity Log (MAL) (F-ArmA)

Stroke

France
St. Luke's Medical Center, Philippines

Terminated

Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features

Gastro Esophageal Reflux | GERD

Philippines
Novartis Pharmaceuticals

Recruiting

Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa. (ANIMA)

Hidradenitis Suppurativa

Germany
Technical University of Munich
Novartis

Completed

Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum

Pyoderma Gangrenosum

Germany
Novartis Pharmaceuticals

Completed

Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Thailand
Novartis Pharmaceuticals

Completed

Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

United States
University of Erlangen-Nürnberg Medical School

Active, not recruiting

EBIO - Enthesitis Biopsy Study (EBIO)

Psoriatic Arthritis | Enthesitis | Biopsy

Germany
Novartis Pharmaceuticals

Completed

Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence Study

Psoriatic Arthritis | Axial Spondyloarthritis

Spain
Novartis Pharmaceuticals

Completed

Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis

Psoriasis

United States
Saakshi Khattri

Completed

A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis

Psoriasis

United States
Novartis Pharmaceuticals

Completed

A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China (UNMASK2)

Psoriasis

China
Novartis Pharmaceuticals

Terminated

Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis (SELUNE)

Lupus Nephritis

China, Croatia, Czechia, Russian Federation, Turkey, Australia, Spain, Thailand, Argentina, United States, Denmark, Greece, Romania, Germany, Korea, Republic of, India, Brazil, Japan, Peru, Portugal, Italy, Taiwan, Vietnam, Norway, Colo... and more
Novartis Pharmaceuticals

Completed

An Analysis of the Improvement and Quality of Life Trends for UK/ROI Patients Treated With Cosentyx (Secukinumab) in a Retrospective Analysis of the BADBIR Data Source

Plaque Psoriasis

United States
Mayo Clinic

Completed

Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris

PITYRIASIS RUBRA PILARIS

United States
Narrows Institute for Biomedical Research
Novartis

Unknown

Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT).

Psoriasis Vulgaris

United States
Icahn School of Medicine at Mount Sinai
Novartis

Completed

Secukinumab for Treatment of Atopic Dermatitis

Atopic Dermatitis

United States
Tufts Medical Center

Completed

Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States
Novartis Pharmaceuticals

Completed

Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants. (SIGNATURE)

Psoriasis

United Kingdom, Ireland
Assistance Publique - Hôpitaux de Paris

Recruiting

Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. (ARCACHON)

Coronary Artery Disease | Percutaneous Coronary Intervention | Coronary Artery Bypass Grafting

France
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.

Psoriatic Arthritis

China
Novartis Pharmaceuticals

Recruiting

Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis (SPARROW)

Moderate-to-severe Plaque Psoriasis

Russian Federation
Novartis Pharmaceuticals

Recruiting

Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR

Giant Cell Arteritis | Polymyalgia Rheumatica

United States, Switzerland
Novartis Pharmaceuticals

Available

Secukinumab Global MAP Cohort for Adult Patients With Hidradenitis Suppurativa (HS)

Hidradenitis Suppurativa (HS)
University of California, San Francisco
Novartis Pharmaceuticals

Completed

Immunologic Response to Secukinumab in Plaque Psoriasis

Psoriasis

United States
Anne Chang

Completed

Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea

Papulopustular Rosacea

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...
Novartis

Completed

Mechanism of Action of Anti-IL17 Therapy in Peripheral Spondyloarthritis (MoA aIL-17)

Spondylarthropathies

Netherlands
Taizhou Mabtech Pharmaceutical Co.,Ltd

Completed

Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers

Psoriasis

China
Novartis Pharmaceuticals

Active, not recruiting

2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis (PROMPT)

Psoriatic Arthritis | Ankylosing Spondylitis | Moderate to Severe Plaque Psoriasis | Non-radiographic Axial Spondyloarthritis

Thailand
University Hospital, Ghent
Novartis

Completed

Secukinumab in Active Non-segmental Vitiligo

Vitiligo | Secukinumab

Belgium
University of Erlangen-Nürnberg Medical School

Completed

Psoriasis-Arthritis & Bone Program (PSARTROS)

Psoriasis | Psoriatic Arthritis

Germany
Novartis Pharmaceuticals

Completed

Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis (GAIN)

Moderate to Severe Plaque-type Psoriasis

Germany
Novartis Pharmaceuticals

Completed

Plaque Psoriasis Efficacy and Safety With Secukinumab (OPTIMISE)

Plaque Psoriasis

Germany, Belgium, Spain, Croatia, Czechia, Greece, Hungary, Russian Federation, Netherlands, Austria, France, Switzerland, Israel, United Kingdom, Italy, Lithuania, Sweden, Bulgaria, Denmark, Finland, Portugal, Slovakia, Poland, Latvia
Novartis Pharmaceuticals

Completed

Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)

Psoriasis

Japan
Johnson & Johnson Consumer Inc. (J&JCI)

Completed

A Study of 3 Investigational Products on the Microbiome and Scalp Attributes in Children With Curly Hair

Healthy

Brazil
Seqirus

Completed

Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults

Influenza

Australia, New Zealand, Philippines, South Africa
Novartis Pharmaceuticals

Completed

24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis

Psoriatic Arthritis

United Kingdom, Germany, Italy, Spain, United States, Australia, Bulgaria, Russian Federation, Czechia, Canada, Netherlands, Switzerland, Puerto Rico
Novartis Pharmaceuticals

Completed

Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA

Ankylosing Spondylitis

India, Turkey, Belgium, Thailand, United States, Czechia, Greece, Russian Federation, Bulgaria, Guatemala, Italy, Korea, Republic of, Malaysia, Sweden, Colombia, Philippines, Poland, Brazil
Novartis Pharmaceuticals

Terminated

A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) (ORBIT)

Thyroid Eye Disease | Graves Orbitopathy

Germany
Chinese University of Hong Kong

Completed

PsA Secukinumab XCT Structural Progression Study

Psoriatic Arthritis

Hong Kong
Jinnah Postgraduate Medical Centre

Completed

Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital.

Plaque Psoriasis

Pakistan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

Moderate to Severe Chronic Plaque-type Psoriasis

United States, Hungary, Italy, Russian Federation, Germany, Czechia, Canada
Novartis Pharmaceuticals

Terminated

Safety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled Asthma

Asthma

Germany, United Kingdom
Novartis Pharmaceuticals

Completed

Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients (ObePso-S)

Plaque Psoriasis

United States

3

Subscribe